A Phase 2 interventional study of Cannabigerol and Placebo in Attention-Deficit/Hyperactivity Disorder, sponsored by University of Arkansas, Fayetteville. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Arkansas, Fayetteville · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 366th largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2024, is one of 80 in phase 2, and was the 710th registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 32 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 72 across 1,439 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
University of Arkansas, Fayetteville is the lead sponsor of 29 studies on the registry; 7 are open to participants now.
University of Arkansas, Fayetteville has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
35 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02736656Phase 3Supernus Pharmaceuticals, Inc.Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | 2026-12 |
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
Add all 35 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes (PANAS only) and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
The criteria were revised on the registry on Nov 19, 2026. See what changed
Not currently prescribed or taking the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1mL of 80mg of Cannabigerol. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant.
Drug: Cannabigerol
1mL of Placebo. Placebo is made in the form of MCT oil.
Other: Placebo
1 mL of 80mg Cannabigerol once during experimental session
1 mL of placebo once during experimental session
Sustained Attention to Response Task
A computerized task that measures response inhibition.
Time frame: 75 minutes post CBG/placebo administration
Trail Making Test-Parts A and B (TMT-A&B)
A paper-and-pencil task that measures attention, psychomotor speed, and cognitive flexibility.
Time frame: 75 minutes post CBG/placebo administration
Digit Symbol Substitution Test (DSST)
A paper-and-pencil task that measures attention/processing speed.
Time frame: 75 minutes post CBG/placebo administration
Rey Auditory Verbal Learning Test (AVLT)
A paper-and-pencil/verbal test that measures verbal memory.
Time frame: 75 minutes post CBG/placebo administration
Iowa Gambling Task (IGT)
A computerized task that measures decision making (an indicator of impulsivity/hyperactivity).
Time frame: 75 minutes post CBG/placebo administration
Positive and Negative Affect Scale-Expanded Version
Self-report measure of positive and negative affect. Scores range from 30-150 on each of the two types of affects, with higher scores representing greater affect.
Time frame: Baseline, 45 minutes post CBG/placebo administration, 75 minutes post CBG/placebo administration
Karolinska Sleepiness Scale
Self-report measure of subjective level of sleepiness at a particular time during the day. Scores range from 1-10, with higher scores representing greater sleepiness.
Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration
Brief Irritability Test
Self-report measure of irritability. Scores range from 5-30, with higher scores representing greater irritability.
Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration
Numeric Rating Scale (pain)
Self-report measure of subjective level of pain. Scores range from 0-10, with higher scores representing greater pain.
Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration
State-Trait Anxiety Inventory (State Version)
Self-report measure of state anxiety. Scores range from 20 to 80 with higher scores indicating greater anxiety.
Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration
Visual Analog Scales
Self-report of state-like states (e.g., anxiety, hunger). This scale ranges from 0 to 100 with higher scores indicating higher levels of the indication.
Time frame: 75 minutes post CBG/placebo administration
Global Impression of Change
Self-report measure of perceived change in ADHD symptoms. This scale ranges from 1 to 7 with higher scores indicating greater improvements.
Time frame: 75 minutes post CBG/placebo administration
Plan to share: Yes — De-identified, individual participant data (including data dictionaries) that underlie results reported in each published report will be shared (text, tables, figures, appendices)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 9months and ending 36 months following publication
Access criteria: Researchers who provide a methodologically sound proposal. Inquiries should be directed to eleenfe@uark.edu; Requestors will need to sign a data agreement to gain access
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Jul 2026, 19 months.
Of 40 phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 40. This study's 19 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabigerol
Attention Deficit Disorder with Hyperactivity →
University of Arkansas, Fayetteville